TY - JOUR
T1 - International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV)
T2 - Content and implementation in daily routine practice
AU - Jordan, Karin
AU - Gralla, Richard
AU - Jahn, Franziska
AU - Molassiotis, Alex
PY - 2014/2/5
Y1 - 2014/2/5
N2 - Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.
AB - Over the past decades major improvements in the management of chemotherapy induced nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV can be prevented in almost 70%, and even up to, 80% of patients. Treatment guidelines enable physicians to integrate the latest clinical research into their daily practice. The large volume of rapidly evolving clinical data has been summarised and incorporated into treatment recommendations by well-known and reliable institutions. These organisations include the Multinational Association of Supportive Care in Cancer (MASCC), the European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN). However, despite the availability of these guidelines, there is an emerging evidence that adherence to, and implementation of, treatment recommendations is less than optimal. This review will especially focus on the content of the current antiemetic guidelines and will address the important question of how these guidelines are implemented in routine practice.
KW - 5-HT serotonin receptor antagonists
KW - ASCO antiemetic guidelines
KW - Antiemetic therapy
KW - MASCC/ESMO antiemetic guidelines
KW - NCCN practice antiemesis guidelines
KW - Neurokinin receptor antagonist
UR - http://www.scopus.com/inward/record.url?scp=84892883297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892883297&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2013.09.073
DO - 10.1016/j.ejphar.2013.09.073
M3 - Review article
C2 - 24157984
AN - SCOPUS:84892883297
SN - 0014-2999
VL - 722
SP - 197
EP - 202
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -